Published Wed, 06 Jun 2018 13:50:22 on Interactive Investor
Four very different small caps - Oxford BioMedica (OXB), Alpha Financial (AFM), Tricorn (TCN), and MS International (MSI) - repaid the faith of investors today with some spectacular share price gains.
Aside from their double-digit percentage rises, the quartet have some interesting stories to tell, not least the announcement by Oxford BioMedica concerning the development of its gene therapy treatment for Parkinson's.
Its licensing agreement with Axovant Sciences, a clinical-stage biopharma company, will accelerate the development of OXB-102 in an effort to address a disease which has a high unmet medical need.
Oxford BioMedica will receive a total of $842.5 million dependent on development, regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD - as the therapy will now be known.
Peel Hunt immediately raised its price target to 1010p from 780p. Oxford Biomedica has been on the stockmarket since the mid 1990s, with shares hitting their all-time peak during the dotcom boom.
Source: interactive investor Past performance is not a guide to future performance
In contrast, Alpha Financial Markets Consulting, which provides specialist consultancy services to the asset and wealth management industry, is celebrating its first set of results following its AIM admission in October.
Today's figures show the continued benefit of "deep-rooted change" within the industry, with pressure on fees and... Read more